Other languages Polaris Group

Equities

6550

KYG7171A1085

End-of-day quote Taiwan S.E. Other stock markets 03:30:00 03/05/2024 am IST			5-day change	1st Jan Change
69.5 ^TWD	-1.00%		+5.78%	-8.07%

2023	Polaris Group Announces the Appointment of K Evin Wu	CI
2023	Polaris Group Announces Chief Executive Officer Changes, Effective December 21, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Polaris Group Announces the Appointment of K Evin Wu	21/12
Polaris Group Announces Chief Executive Officer Changes, Effective December 21, 2023	21/12
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20 in Phase II Clinical Trial for NASH at Chang Gung Memorial Hospital, Linkou, Taiwan	29/11
Polaris Group Initiates Rolling Submission of Biologic License Application for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	17/11
Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11/11
Polaris Group Appoints K.C. Tsai as Compensation Committee Member	26/23/26
Polaris Group Announces of Resignation of TAI, JANG-HUEI as Independent Director	29/23/29
Polaris Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/23/25
Polaris Group Announces Dosing of First Patient in Phase 2 Trial of ADI-PEG 20 with Radiation and TMZ in Patients with GBM	04/23/04
Polaris Group Partners with MatrixCare to Improve MDS Assessment Accuracy for Long-Term Care Communities	27/23/27
Polaris Group Announces MFDS Approves Phase Phase 2 Clinical Protocol Treating GBM with ADI-PEG 20	27/23/27
Polaris Group Appoints Chien-Hsing Chang as Chief Strategy Officer Effective June 20, 2023	12/23/12
Polaris Group Announces Executive Changes Effective June 15, 2023	12/23/12
Polaris Group Announces that TFDA Approves Phase3 Clinical Protocol Treatment HCC with ADI-PEG 20	30/23/30
Polaris Group and Vietnam National Cancer Center Announce the Signing of MOU for Future Collaboration	29/23/29
Polaris Group Submits ADI-PEG 20 to TFDA for INR as Treatment for Hepatocellular Carcinoma	04/23/04
Polaris Group Announces the Submission of Polyaris 2020-001 Phase 2 Trial of ADI-PEG 20 to MFDS	13/23/13
Polaris Group Receives Pre-BLA Meeting Notice from US FDA for ADI-PEG 20	03/23/03
Polaris Group Receives IND Approval from US FDA for the Investigational New Drug of ADI-PEG 20 to Treat Soft Tissue Sarcoma	21/23/21
Polaris Group Announces the Signing of MOU with National Health Research Institutes of Taiwan for Future Research Collaboration	27/22/27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Polaris Group

Equities

6550

KYG7171A1085

Other languages

Filters